Collection

Early access to medicines scheme (EAMS): scientific opinions

Information on granted EAMS scientific opinions, including the public assessment report and treatment protocols.

Published 3 June 2015
Last updated 3 August 2018 — see all updates

• From: Medicines and Healthcare products Regulatory Agency

See expired scientific opinions.

Current EAMS

1. Early access to medicines scheme (EAMS) scientific opinion: Raxone to treat the decline of respiratory function in patients with Duchenne Muscular Dystrophy
   • 21 June 2018
   • Decision
2. Early access to medicines scheme (EAMS) scientific opinion: Volanesorsen as a treatment of adult patients with familial chylomicronaemia syndrome
   • 4 June 2018
   • Decision

Published 3 June 2015
Last updated 3 August 2018 + show all updates

1. 3 August 2018 Added patisiran-LNP to treat adults with hereditary transthyretin-mediated amyloidosis.
2. 20 March 2018 Early Access to Medicines Scientific Opinion on Volanesorsen to treat adult patients with familial chylomicronaemia syndrome
3. 2 January 2018 Amended to add the positive scientific opinion for emicizumab for routine prophylaxis of bleeding episodes in patients, aged 1 year and over, with haemophilia A with factor VIII inhibitors
4. 21 December 2017 Added Nivolumab to treat advanced or recurrent gastric or gastroesophageal junction cancer after two or more systemic therapies to current EAMS opinions.
5. 29 September 2017 Removed Dupilumab (for severe atopic dermatitis) from current EAMS as this product received a marketing authorisation from the European Commission.
6. 1 September 2017 Link to the EAMS Scientific Opinion for Alectinib has been added to the page.
7. 21 June 2017 New EAMS scientific opinion for Raxone added to the collections page.
8. 7 June 2017 New EAMS scientific opinion for Oxervate added to the page.
9. 11 May 2017 Added EAMS scientific opinion: Glecaprevir/Pibrentasvir for the treatment of chronic hepatitis C (HCV) infection in adults
10. 13 March 2017 EAMS for Dupilumab published
11. 1 February 2017 SO for pembrolizumab for non-small cell lung cancer removed from current EAMS list.
12. 23 January 2017 New EAMS positive scientific opinion
13. 23 November 2016 Nivolumab to treat a type of cancer of the Lymph system - the Scientific Opinion has now expired due to a positive EC decision
14. 23 August 2016 Added link to the scientific opinion: venetoclax for the treatment of chronic lymphocytic leukaemia (CLL)
15. 8 December 2015 Added: Early access to medicines scheme (EAMS) scientific opinion: osimertinib (AZD9291) 40 and 80mg film-coated tablets
16. 1 September 2015 New EAM issued to Novartis for sacubitril-valsartan
17. 3 June 2015 First published.